Camrelizumab、Rivoceranib + Camrelizumab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Conditions

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Trial Timeline

Sep 1, 2022 → Nov 15, 2024

NCT ID

NCT05367687

About Camrelizumab、Rivoceranib + Camrelizumab

Camrelizumab、Rivoceranib + Camrelizumab is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation. The current trial status is completed. This product is registered under clinical trial identifier NCT05367687. Target conditions include Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.

What happened to similar drugs?

2 of 4 similar drugs in Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation were approved

Approved (2) Terminated (0) Active (2)

🔄SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3

✅Fluad + SalineNovartisApproved

✅LetrozoleNovartisApproved

🔄Elinzanetant (BAY3427080) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05367687	Phase 2	Completed	Sep 1, 2022	Nov 15, 2024	Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Competing Products

9 competing products in Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

See all competitors

Product	Company	Stage	Hype Score
SHR-A1811 + Trastuzumab Emtansine	Jiangsu Hengrui Medicine	Phase 3	47
Fluad + Saline	Novartis	Approved	43
Letrozole	Novartis	Approved	39
Biomarker Testing	Roche	Pre-clinical	22
Fluorouracile + Epirubicin + Cyclophosphamide + Letrozole + Palbociclib	Pfizer	Phase 2	35
Elinzanetant (BAY3427080) + Placebo	Bayer	Phase 3	41
Zanzalintinib	Exelixis	Phase 2	39
E7046 + capecitabine + folinic acid/5-FU/oxaliplatin (mFOLFOX-6)	Adlai Nortye	Phase 1	19
Pembrolizumab, Eftilagimod alfa	Immutep	Phase 2	29